

# Christopher B Umbricht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3349906/publications.pdf>

Version: 2024-02-01

37  
papers

1,856  
citations

394421

19  
h-index

330143

37  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 391-401.	1.7	5
2	Characterization of <i>TERT</i> and <i>BRAF</i> copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 403-409.	2.8	15
3	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. <i>Clinical Epigenetics</i> , 2021, 13, 104.	4.1	10
4	Retrospective analysis of cancer-specific gene expression panel for thyroid fine needle aspiration specimens. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2983-2991.	2.5	1
5	Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay. <i>Cancers</i> , 2020, 12, 2772.	3.7	18
6	Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review. <i>Frontiers in Endocrinology</i> , 2020, 11, 485.	3.5	33
7	Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines. <i>Molecular Oncology</i> , 2020, 14, 2355-2357.	4.6	5
8	<i>TERT</i> promoter mutation determines apoptotic and therapeutic responses of <i>BRAF</i> -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15846-15851.	7.1	31
9	Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines. <i>Thyroid</i> , 2020, 30, 1470-1481.	4.5	14
10	Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 695-706.	2.5	19
11	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 3.	5.2	15
12	Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women's Health Initiative. <i>Thyroid</i> , 2020, 30, 519-530.	4.5	19
13	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	7.0	21
14	Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 530-540.	2.8	21
15	Measuring DNA Copy Number Variation Using High-Density Methylation Microarrays. <i>Journal of Computational Biology</i> , 2019, 26, 295-304.	1.6	12
16	Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 689-702.	2.5	32
17	Preoperative Molecular Markers in Thyroid Nodules. <i>Frontiers in Endocrinology</i> , 2018, 9, 179.	3.5	44
18	Integrated Genomic Analysis of <i>HeLa</i> Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	16.8	195

#	ARTICLE	IF	CITATIONS
19	Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: Time for a Reset?. <i>Thyroid</i> , 2017, 27, 1393-1399.	4.5	25
20	Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma. <i>Journal of Proteomics</i> , 2017, 166, 59-67.	2.4	20
21	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 751-758.	1.6	110
22	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4390-4397.	1.6	51
23	Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review). <i>International Journal of Oncology</i> , 2016, 49, 2199-2205.	3.3	34
24	Morphologically compatible mass spectrometric analysis of lipids in cytological specimens. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 3-8.	0.5	6
25	Association of <i>BRAF</i> <sup>V600E</sup> Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. <i>Thyroid</i> , 2016, 26, 532-542.	4.5	50
26	MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review. <i>Thyroid</i> , 2015, 25, 1322-1329.	4.5	71
27	Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?. <i>PLoS ONE</i> , 2014, 9, e105545.	2.5	20
28	Lower Vitamin D Levels in Surgical Hyperparathyroidism versus Thyroid Patients. <i>American Surgeon</i> , 2014, 80, 505-510.	0.8	6
29	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. <i>Cancer Research</i> , 2014, 74, 2160-2170.	0.9	149
30	An estimation model for Oncotype DX recurrence score using routine histopathologic variables.. <i>Journal of Clinical Oncology</i> , 2014, 32, 559-559.	1.6	1
31	Modeling precision treatment of breast cancer. <i>Genome Biology</i> , 2013, 14, R110.	9.6	264
32	Three-Gene Molecular Diagnostic Model for Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 275-284.	4.5	37
33	Telomere Length Is Related to Alternative Splice Patterns of Telomerase in Thyroid Tumors. <i>American Journal of Pathology</i> , 2011, 179, 1415-1424.	3.8	19
34	DNA methylation-related vitamin D receptor insensitivity in breast cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 44-53.	3.4	85
35	Identification of Genes Differentially Expressed in Benign versus Malignant Thyroid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3327-3337.	7.0	77
36	Human Telomerase Reverse Transcriptase Gene Expression and the Surgical Management of Suspicious Thyroid Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 5762-5768.	7.0	32

#	ARTICLE	IF	CITATIONS
37	Hypermethylation of 14-3-3 $\bar{f}$ (stratifin) is an early event in breast cancer. <i>Oncogene</i> , 2001, 20, 3348-3353.	5.9	284